Daniel Yao, MD
Urology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: El Camino Health · Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Yao’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A83102 · Current
Licensed to practise in California · since 2003 · expires 2028-09-30 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$327,854
Medicare paid this office $327,854 for 686 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 550 | $105,415 | $110 |
| Diagnostic exam of bladder and urethra using an endoscope | 135 | $43,000 | $249 |
| Long return visit (40+ min) | 154 | $38,455 | $164 |
| New patient visit (45+ min) | 120 | $17,333 | $144 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 570 | $14,787 | $14 |
See all 19 services
| Return visit (30+ min) | 550 | $105,415 | $110 |
| Diagnostic exam of bladder and urethra using an endoscope | 135 | $43,000 | $249 |
| Long return visit (40+ min) | 154 | $38,455 | $164 |
| New patient visit (45+ min) | 120 | $17,333 | $144 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 570 | $14,787 | $14 |
| Waterjet destruction of prostrate accessed through the urethra | 17 | $10,717 | $630 |
| Short return visit (20+ min) | 94 | $9,725 | $85 |
| Biopsy of prostate gland | 38 | $9,008 | $237 |
| Ultrasound scan of pelvic region through rectum | 47 | $7,419 | $148 |
| Other ultrasound procedure | 28 | $6,943 | $248 |
| Dilation of urethra using an endoscope | 12 | $5,027 | $335 |
| New patient visit (60+ min) | 14 | $2,710 | $194 |
| Ultrasound measurement of bladder capacity after voiding | 151 | $2,648 | $12 |
| Hospital discharge day management, more than 30 minutes | 21 | $2,177 | $104 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $772 | $30 |
| Electronic assessment of bladder emptying | 62 | $645 | $9 |
| Injection of drug or substance under skin or into muscle | 23 | $462 | $14 |
| Automated urinalysis test | 89 | $238 | $2 |
| Injection, garamycin, gentamicin, up to 80 mg | 37 | $67 | None |
Procedures Medicare counted
| Prostate resection | 15 | More than 70% of doctors who do this |
Who their Medicare patients are
686 Original Medicare patients in 2024. Average age 77 · Women 11% · Also on Medicaid 5% · Health risk score 0.95. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 62% · Cancer 37% · Coronary heart disease 26% · Chronic kidney disease 18% · Atrial fibrillation 18% · Diabetes 17% · Heart failure 10% · Depression 9% · COPD 5% · Dementia 5% · Stroke 5%.
The office billed $1,416,484, Medicare allowed $435,618 and paid $327,854; for 3,537 services of 77 kinds; $4,264 of it was for drugs given in the office and $323,591 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 686 | 3,537 | 77 | 0.95 | $1,416,484 | $327,854 |
| 2023 | 682 | 2,519 | 77 | 0.92 | $1,300,177 | $311,141 |
| 2022 | 646 | 2,719 | 77 | 0.98 | $1,378,438 | $335,664 |
| 2021 | 614 | 2,444 | 77 | 0.97 | $1,260,576 | $304,852 |
| 2020 | 586 | 2,375 | 76 | 1.00 | $1,112,851 | $253,218 |
| 2019 | 634 | 3,610 | 76 | 1.02 | $1,298,459 | $275,987 |
| 2018 | 567 | 2,219 | 75 | 0.99 | $1,065,454 | $223,897 |
| 2017 | 518 | 1,987 | 76 | 1.04 | $1,026,795 | $210,321 |
| 2016 | 519 | 1,747 | 76 | 1.03 | $858,402 | $191,207 |
| 2015 | 508 | 1,792 | 75 | 1.00 | $866,166 | $197,922 |
| 2014 | 481 | 1,807 | 75 | 0.96 | $963,424 | $208,764 |
| 2013 | 428 | 1,531 | 74 | 1.05 | $880,849 | $181,234 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Return visit (30+ min) | 511 | $101,032 | $112 |
| Diagnostic exam of bladder and urethra using an endoscope | 109 | $35,115 | $256 |
| Long return visit (40+ min) | 137 | $30,622 | $166 |
| New patient visit (45+ min) | 155 | $22,706 | $146 |
| Waterjet destruction of prostrate accessed through the urethra | 24 | $16,191 | $675 |
| Insertion of lower leg neurostimulator electrode | 22 | $12,360 | $121 |
| Biopsy of prostate gland | 38 | $9,001 | $231 |
| Short return visit (20+ min) | 82 | $8,364 | $85 |
| Ultrasound scan of pelvic region through rectum | 36 | $5,056 | $140 |
| Other ultrasound procedure | 13 | $3,245 | $232 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $3,238 | $249 |
| Ultrasound measurement of bladder capacity after voiding | 153 | $2,433 | $11 |
| Hospital discharge day management, 30 minutes or less | 26 | $1,955 | $75 |
| Injection of drug or substance under skin or into muscle | 32 | $500 | $14 |
| 3d radiographic procedure with computerized image postprocessing | 14 | $492 | $35 |
| Electronic assessment of bladder emptying | 39 | $408 | $9 |
| Automated urinalysis test | 144 | $385 | $2 |
| Injection, garamycin, gentamicin, up to 80 mg | 37 | $87 | None |
2022: 22 services
| Return visit (30+ min) | 495 | $100,500 | $110 |
| Diagnostic exam of bladder and urethra using an endoscope | 124 | $41,477 | $261 |
| Long return visit (40+ min) | 138 | $34,611 | $169 |
| Insertion of lower leg neurostimulator electrode | 31 | $17,796 | $124 |
| New patient visit (45+ min) | 120 | $15,552 | $130 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $13,078 | None |
| Waterjet destruction of prostrate accessed through the urethra | 17 | $11,455 | $674 |
| Biopsy of prostate gland | 42 | $10,723 | $249 |
| Ultrasound scan of pelvic region through rectum | 41 | $6,370 | $148 |
| Short return visit (20+ min) | 58 | $5,835 | $85 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 14 | $4,738 | $226 |
| Ultrasound measurement of bladder capacity after voiding | 169 | $2,519 | $11 |
| Simple insertion of temporary bladder tube | 16 | $2,474 | $62 |
| New patient visit (60+ min) | 13 | $2,375 | $183 |
| 3d radiographic procedure with computerized image postprocessing | 29 | $1,036 | $36 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $743 | $35 |
| Injection of drug or substance under skin or into muscle | 43 | $681 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $517 | $24 |
| Automated urinalysis test | 140 | $395 | $2 |
| Electronic assessment of bladder emptying | 37 | $305 | $8 |
| Injection, garamycin, gentamicin, up to 80 mg | 26 | $42 | None |
| Injection, tobramycin sulfate, up to 80 mg | 15 | $28 | None |
2021: 23 services
| Return visit (30+ min) | 425 | $80,806 | $114 |
| Diagnostic exam of bladder and urethra using an endoscope | 100 | $35,063 | $250 |
| Long return visit (40+ min) | 125 | $32,929 | $169 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $20,229 | None |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 14 | $18,034 | $1,288 |
| New patient visit (45+ min) | 114 | $16,625 | $146 |
| Insertion of lower leg neurostimulator electrode | 33 | $14,933 | $137 |
| Biopsy of prostate gland | 35 | $9,213 | $256 |
| Short return visit (20+ min) | 73 | $6,148 | $73 |
| Ultrasound scan of pelvic region through rectum | 30 | $4,892 | $153 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 14 | $4,325 | $309 |
| Simple insertion of temporary bladder tube | 16 | $1,994 | $59 |
| Ultrasound measurement of bladder capacity after voiding | 132 | $1,963 | $11 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,506 | $94 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $1,291 | $34 |
| 3d radiographic procedure with computerized image postprocessing | 30 | $1,087 | $36 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 21 | $779 | $31 |
| Insertion of stent in ureter using an endoscope | 11 | $751 | $68 |
| Injection of drug or substance under skin or into muscle | 40 | $660 | $14 |
| Automated urinalysis test | 155 | $455 | $2 |
| Electronic assessment of bladder emptying | 20 | $173 | $8 |
| Manual urinalysis test with examination using microscope, automated | 22 | $70 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 39 | $60 | None |
2020: 22 services
| Return visit (30+ min) | 321 | $49,428 | $95 |
| Diagnostic exam of bladder and urethra using an endoscope | 107 | $30,875 | $216 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $27,610 | None |
| Short return visit (20+ min) | 235 | $18,124 | $62 |
| Insertion of lower leg neurostimulator electrode | 21 | $10,782 | $131 |
| Biopsy of prostate gland | 39 | $9,849 | $246 |
| Long return visit (40+ min) | 53 | $9,642 | $138 |
| New patient visit (45+ min) | 65 | $9,090 | $140 |
| New patient visit (30+ min) | 66 | $5,245 | $79 |
| Ultrasound scan of pelvic region through rectum | 28 | $4,530 | $156 |
| Simple insertion of temporary bladder tube | 20 | $2,871 | $57 |
| Telephone medical discussion with physician, 11-20 minutes | 30 | $2,450 | $68 |
| Ultrasound measurement of bladder capacity after voiding | 135 | $1,767 | $10 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | $1,707 | $107 |
| Insertion of stent in ureter using an endoscope | 14 | $1,562 | $92 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,470 | $33 |
| Injection of drug or substance under skin or into muscle | 40 | $602 | $14 |
| Automated urinalysis test | 168 | $472 | $2 |
| Telephone medical discussion with physician, 5-10 minutes | 11 | $458 | $42 |
| Electronic assessment of bladder emptying | 20 | $220 | $9 |
| Injection, garamycin, gentamicin, up to 80 mg | 39 | $63 | None |
| Manual urinalysis test with examination using microscope, automated | 13 | $41 | $3 |
2019: 23 services
| Return visit (30+ min) | 305 | $47,602 | $98 |
| Diagnostic exam of bladder and urethra using an endoscope | 132 | $31,840 | $192 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $26,780 | None |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 18 | $23,250 | $1,292 |
| Short return visit (20+ min) | 245 | $19,018 | $61 |
| Long return visit (40+ min) | 79 | $13,254 | $133 |
| New patient visit (45+ min) | 73 | $10,277 | $141 |
| Insertion of lower leg neurostimulator electrode | 20 | $10,039 | $132 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $7,399 | $673 |
| New patient visit (30+ min) | 80 | $7,226 | $90 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 20 | $6,760 | $322 |
| Biopsy of prostate gland | 26 | $6,470 | $249 |
| Ultrasound scan of pelvic region through rectum | 23 | $2,895 | $126 |
| Ultrasound measurement of bladder capacity after voiding | 153 | $2,422 | $12 |
| Simple insertion of temporary bladder tube | 14 | $1,963 | $63 |
| Insertion of stent in ureter using an endoscope | 12 | $1,942 | $114 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,283 | $32 |
| Automated urinalysis test | 198 | $678 | $2 |
| Injection of drug or substance under skin or into muscle | 31 | $551 | $16 |
| 3d radiographic procedure with computerized image postprocessing | 13 | $508 | $39 |
| Manual urinalysis test with examination using microscope, automated | 35 | $135 | $3 |
| Electronic assessment of bladder emptying | 16 | $120 | $7 |
| Injection, garamycin, gentamicin, up to 80 mg | 26 | $39 | None |
2018: 17 services
| Return visit (30+ min) | 263 | $37,656 | $93 |
| Diagnostic exam of bladder and urethra using an endoscope | 134 | $27,401 | $161 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $21,663 | None |
| Short return visit (20+ min) | 235 | $19,079 | $58 |
| Long return visit (40+ min) | 64 | $10,946 | $129 |
| New patient visit (45+ min) | 78 | $10,862 | $139 |
| New patient visit (30+ min) | 76 | $7,280 | $96 |
| Biopsy of prostate gland | 23 | $5,648 | $246 |
| Ultrasound scan of pelvic region through rectum | 23 | $2,468 | $99 |
| Ultrasound measurement of bladder capacity after voiding | 124 | $2,404 | $16 |
| Insertion of stent in ureter using an endoscope | 17 | $1,305 | $73 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $909 | $30 |
| Injection of drug or substance under skin or into muscle | 27 | $700 | $21 |
| Automated urinalysis test | 177 | $621 | $3 |
| 3d radiographic procedure with computerized image postprocessing | 11 | $393 | $36 |
| Manual urinalysis test with examination using microscope, automated | 57 | $238 | $4 |
| Injection, garamycin, gentamicin, up to 80 mg | 27 | $34 | None |
2017: 21 services
| Return visit (30+ min) | 240 | $31,549 | $87 |
| Diagnostic exam of bladder and urethra using an endoscope | 122 | $23,614 | $155 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $19,166 | None |
| Short return visit (20+ min) | 221 | $15,673 | $56 |
| Long return visit (40+ min) | 67 | $10,450 | $131 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $8,263 | $751 |
| New patient visit (45+ min) | 58 | $7,583 | $131 |
| New patient visit (30+ min) | 76 | $6,924 | $91 |
| Insertion of lower leg neurostimulator electrode | 15 | $3,788 | $126 |
| Biopsy of prostate gland | 15 | $3,342 | $223 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 12 | $2,503 | $209 |
| Ultrasound measurement of bladder capacity after voiding | 103 | $2,336 | $19 |
| Ultrasound scan of pelvic region through rectum | 16 | $1,640 | $96 |
| Insertion of stent in ureter using an endoscope | 15 | $1,355 | $75 |
| Ultrasonic guidance for needle placement | 17 | $1,059 | $56 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $851 | $33 |
| Automated urinalysis test | 175 | $632 | $3 |
| Injection of drug or substance under skin or into muscle | 19 | $540 | $26 |
| Manual urinalysis test with examination using microscope, automated | 42 | $196 | $4 |
| Electronic assessment of bladder emptying | 13 | $122 | $8 |
| Injection, garamycin, gentamicin, up to 80 mg | 16 | $20 | None |
2016: 17 services
| Diagnostic exam of bladder and urethra using an endoscope | 140 | $32,811 | $193 |
| Return visit (30+ min) | 236 | $31,325 | $89 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $15,512 | None |
| Short return visit (20+ min) | 197 | $13,791 | $56 |
| New patient visit (45+ min) | 75 | $10,514 | $140 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 14 | $10,503 | $750 |
| Long return visit (40+ min) | 46 | $6,580 | $132 |
| New patient visit (30+ min) | 58 | $5,255 | $91 |
| Insertion of lower leg neurostimulator electrode | 19 | $5,030 | $129 |
| Biopsy of prostate gland | 16 | $2,944 | $184 |
| Ultrasound measurement of bladder capacity after voiding | 100 | $2,298 | $19 |
| Complicated insertion of bladder tube | 11 | $1,586 | $122 |
| Ultrasonic guidance for needle placement | 16 | $969 | $57 |
| Automated urinalysis test | 168 | $606 | $3 |
| Injection of drug or substance under skin or into muscle | 17 | $446 | $25 |
| Manual urinalysis test with examination using microscope, automated | 38 | $182 | $4 |
| Injection, garamycin, gentamicin, up to 80 mg | 14 | $16 | None |
2015: 18 services
| Diagnostic exam of bladder and urethra using an endoscope | 111 | $28,783 | $201 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $28,544 | None |
| Return visit (30+ min) | 188 | $24,478 | $92 |
| Short return visit (20+ min) | 258 | $20,731 | $58 |
| New patient visit (45+ min) | 53 | $7,940 | $150 |
| Long return visit (40+ min) | 36 | $6,476 | $138 |
| New patient visit (30+ min) | 53 | $5,139 | $97 |
| Biopsy of prostate gland | 21 | $4,413 | $210 |
| Insertion of lower leg neurostimulator electrode | 14 | $4,047 | $123 |
| Ultrasound measurement of bladder capacity after voiding | 79 | $1,775 | $19 |
| Ultrasound scan of pelvic region through rectum | 21 | $1,718 | $82 |
| Simple insertion of temporary bladder tube | 11 | $1,389 | $73 |
| Ultrasonic guidance for needle placement | 22 | $1,180 | $54 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $1,012 | $34 |
| Injection of drug or substance under skin or into muscle | 30 | $822 | $27 |
| Automated urinalysis test | 148 | $563 | $3 |
| Electronic assessment of bladder emptying | 18 | $200 | $11 |
| Injection, garamycin, gentamicin, up to 80 mg | 24 | $27 | None |
2014: 21 services
| Diagnostic exam of bladder and urethra using an endoscope | 129 | $31,569 | $189 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $24,755 | None |
| Return visit (30+ min) | 177 | $22,441 | $90 |
| Short return visit (20+ min) | 269 | $20,617 | $56 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 12 | $16,710 | $1,392 |
| New patient visit (45+ min) | 88 | $12,212 | $139 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $12,008 | $751 |
| Long return visit (40+ min) | 50 | $7,440 | $124 |
| Biopsy of prostate gland | 26 | $5,627 | $194 |
| Complicated insertion of bladder tube | 19 | $5,020 | $120 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 12 | $3,806 | $317 |
| New patient visit (30+ min) | 39 | $3,422 | $88 |
| Ultrasound scan of pelvic region through rectum | 26 | $2,663 | $92 |
| Ultrasonic guidance for needle placement | 29 | $2,211 | $69 |
| Ultrasound measurement of bladder capacity after voiding | 69 | $1,872 | $18 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $1,135 | $32 |
| Injection of drug or substance under skin or into muscle | 32 | $810 | $25 |
| Electronic assessment of bladder emptying | 22 | $215 | $9 |
| Urinalysis, manual test | 48 | $177 | $3 |
| Automated urinalysis test | 43 | $129 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 29 | $30 | None |
2013: 19 services
| Diagnostic exam of bladder and urethra using an endoscope | 103 | $24,729 | $190 |
| Short return visit (20+ min) | 243 | $19,911 | $57 |
| Return visit (30+ min) | 153 | $18,120 | $87 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $17,254 | None |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 14 | $14,965 | $1,069 |
| New patient visit (45+ min) | 76 | $10,664 | $140 |
| Long return visit (40+ min) | 43 | $7,260 | $123 |
| Ultrasonic guidance for needle placement | 24 | $5,307 | $212 |
| Biopsy of prostate gland | 23 | $4,277 | $186 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 15 | $4,206 | $280 |
| Ultrasound measurement of bladder capacity after voiding | 68 | $1,981 | $19 |
| Ultrasound scan of pelvic region through rectum | 27 | $1,920 | $71 |
| New patient visit (30+ min) | 22 | $1,841 | $84 |
| Insertion of stent in ureter using an endoscope | 16 | $1,016 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $845 | $33 |
| Injection of drug or substance under skin or into muscle | 24 | $693 | $26 |
| Urinalysis, manual test | 34 | $128 | $3 |
| Electronic assessment of bladder emptying | 12 | $119 | $9 |
| Injection, garamycin, gentamicin, up to 80 mg | 23 | $22 | None |
Drugs they prescribed that Part D paid
$265,973
Pharmacies billed $265,973 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (19 of 2,899) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
2,583 generic and 316 brand-name prescriptions · $265,973 in drug cost · 324 antibiotic prescriptions to 142 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 293 | $185,815 | $634 |
| Tamsulosin | 984 | $21,558 | $22 |
| Finasteride | 641 | $10,028 | $16 |
| Mirabegron Er | 22 | $9,428 | $429 |
| Tadalafil | 167 | $6,970 | $42 |
See all 22 drugs
| Myrbetriq | 293 | $185,815 | $634 |
| Tamsulosin | 984 | $21,558 | $22 |
| Finasteride | 641 | $10,028 | $16 |
| Mirabegron Er | 22 | $9,428 | $429 |
| Tadalafil | 167 | $6,970 | $42 |
| Potassium Citrate Er | 50 | $5,068 | $101 |
| Solifenacin | 58 | $4,350 | $75 |
| Silodosin | 47 | $3,856 | $82 |
| Nitrofurantoin | 74 | $2,524 | $34 |
| Alfuzosin Hcl Er | 99 | $1,929 | $19 |
| Oxybutynin Chloride Er | 31 | $908 | $29 |
| Dutasteride | 25 | $894 | $36 |
| Cephalexin | 66 | $520 | $8 |
| Sulfamethoxazole-Trimethoprim | 81 | $330 | $4 |
| Doxazosin Mesylate | 21 | $305 | $15 |
| Nitrofurantoin Mono-Macro | 15 | $165 | $11 |
| Ciprofloxacin | 59 | $148 | $3 |
| Hydrocodone-Acetaminophen | 14 | $125 | $9 |
| Levofloxacin | 15 | $122 | $8 |
| Terazosin | 14 | $114 | $8 |
| Sildenafil Citrate | 11 | $31 | $3 |
| Hydrochlorothiazide | 11 | $29 | $3 |
Year by year
| 2024 | 2,899 | 626 | 1% (19) | 11% | $265,973 |
| 2023 | 2,828 | 582 | 1% (26) | None | $261,527 |
| 2022 | 2,443 | 534 | 1% (33) | 13% | $352,349 |
| 2021 | 1,934 | 456 | 1% (27) | None | $299,541 |
| 2020 | 1,547 | 367 | 2% (29) | None | $253,949 |
| 2019 | 1,413 | 355 | 2% (31) | 12% | $276,154 |
| 2018 | 1,459 | 321 | 3% (38) | None | $166,691 |
| 2017 | 1,383 | 299 | 4% (49) | None | $89,498 |
| 2016 | 1,187 | 257 | 3% (39) | 13% | $78,644 |
| 2015 | 1,257 | 256 | 3% (32) | None | $85,393 |
| 2014 | 1,088 | 225 | 3% (27) | None | $73,289 |
| 2013 | 1,008 | 213 | 4% (35) | None | $58,679 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Myrbetriq | 264 | $174,907 | $663 |
| Tamsulosin | 1,052 | $31,642 | $30 |
| Finasteride | 615 | $11,073 | $18 |
| Silodosin | 65 | $8,311 | $128 |
| Solifenacin | 43 | $5,665 | $132 |
| Potassium Citrate Er | 35 | $4,801 | $137 |
| Darifenacin Er | 12 | $3,000 | $250 |
| Tadalafil | 115 | $2,553 | $22 |
| Oxybutynin Chloride Er | 55 | $2,240 | $41 |
| Alfuzosin Hcl Er | 78 | $2,003 | $26 |
| Nitrofurantoin | 69 | $1,895 | $27 |
| Dutasteride | 29 | $1,348 | $46 |
| Methenamine Hippurate | 12 | $889 | $74 |
| Cephalexin | 63 | $518 | $8 |
| Sulfamethoxazole-Trimethoprim | 58 | $384 | $7 |
| Doxazosin Mesylate | 13 | $257 | $20 |
| Nitrofurantoin Mono-Macro | 14 | $213 | $15 |
| Ciprofloxacin | 52 | $185 | $4 |
| Levofloxacin | 20 | $155 | $8 |
| Sildenafil Citrate | 23 | $136 | $6 |
| Hydrocodone-Acetaminophen | 17 | $88 | $5 |
| Amoxicillin | 11 | $71 | $6 |
| Hydrochlorothiazide | 12 | $29 | $2 |
2022: 19 drugs
| Myrbetriq | 232 | $144,650 | $623 |
| Tamsulosin | 884 | $21,678 | $25 |
| Finasteride | 457 | $7,735 | $17 |
| Solifenacin | 58 | $6,650 | $115 |
| Silodosin | 59 | $4,549 | $77 |
| Oxybutynin Chloride Er | 71 | $3,930 | $55 |
| Potassium Citrate Er | 22 | $3,011 | $137 |
| Nitrofurantoin | 73 | $2,662 | $36 |
| Alfuzosin Hcl Er | 72 | $1,791 | $25 |
| Dutasteride | 37 | $1,138 | $31 |
| Tadalafil | 62 | $1,115 | $18 |
| Methenamine Hippurate | 12 | $968 | $81 |
| Cephalexin | 61 | $569 | $9 |
| Sulfamethoxazole-Trimethoprim | 91 | $533 | $6 |
| Ciprofloxacin | 62 | $319 | $5 |
| Sildenafil Citrate | 26 | $204 | $8 |
| Hydrocodone-Acetaminophen | 26 | $201 | $8 |
| Terazosin | 12 | $190 | $16 |
| Levofloxacin | 11 | $125 | $11 |
2021: 20 drugs
| Xtandi | 12 | $162,187 | $13,516 |
| Myrbetriq | 133 | $73,344 | $551 |
| Tamsulosin | 764 | $17,362 | $23 |
| Finasteride | 292 | $6,537 | $22 |
| Silodosin | 51 | $4,130 | $81 |
| Oxybutynin Chloride Er | 74 | $3,863 | $52 |
| Solifenacin | 56 | $3,280 | $59 |
| Potassium Citrate Er | 12 | $3,196 | $266 |
| Tadalafil | 57 | $2,450 | $43 |
| Nitrofurantoin | 63 | $2,411 | $38 |
| Darifenacin Er | 15 | $1,930 | $129 |
| Alfuzosin Hcl Er | 40 | $1,645 | $41 |
| Dutasteride | 25 | $902 | $36 |
| Cephalexin | 65 | $528 | $8 |
| Nitrofurantoin Mono-Macro | 17 | $502 | $30 |
| Bicalutamide | 15 | $408 | $27 |
| Ciprofloxacin | 63 | $216 | $3 |
| Sulfamethoxazole-Trimethoprim | 46 | $189 | $4 |
| Hydrocodone-Acetaminophen | 22 | $169 | $8 |
| Sildenafil Citrate | 12 | $69 | $6 |
2020: 20 drugs
| Xtandi | 12 | $150,355 | $12,530 |
| Myrbetriq | 106 | $53,083 | $501 |
| Tamsulosin | 564 | $14,103 | $25 |
| Oxybutynin Chloride Er | 117 | $5,934 | $51 |
| Finasteride | 241 | $4,651 | $19 |
| Potassium Citrate Er | 16 | $3,867 | $242 |
| Solifenacin | 27 | $3,034 | $112 |
| Nitrofurantoin | 58 | $2,719 | $47 |
| Tadalafil | 15 | $2,114 | $141 |
| Silodosin | 28 | $2,023 | $72 |
| Dutasteride | 28 | $1,426 | $51 |
| Alfuzosin Hcl Er | 30 | $1,121 | $37 |
| Bicalutamide | 17 | $659 | $39 |
| Cephalexin | 53 | $504 | $10 |
| Doxazosin Mesylate | 12 | $351 | $29 |
| Sulfamethoxazole-Trimethoprim | 49 | $222 | $5 |
| Ciprofloxacin | 60 | $186 | $3 |
| Levofloxacin | 18 | $181 | $10 |
| Allopurinol | 11 | $176 | $16 |
| Hydrocodone-Acetaminophen | 18 | $78 | $4 |
2019: 18 drugs
| Xtandi | 15 | $178,627 | $11,908 |
| Myrbetriq | 64 | $34,875 | $545 |
| Vesicare | 34 | $16,670 | $490 |
| Tamsulosin | 470 | $11,270 | $24 |
| Oxybutynin Chloride Er | 152 | $8,396 | $55 |
| Finasteride | 233 | $5,205 | $22 |
| Potassium Citrate Er | 25 | $4,858 | $194 |
| Silodosin | 19 | $2,799 | $147 |
| Nitrofurantoin | 35 | $1,907 | $54 |
| Dutasteride | 28 | $1,490 | $53 |
| Solifenacin | 15 | $1,101 | $73 |
| Alfuzosin Hcl Er | 27 | $876 | $32 |
| Cephalexin | 75 | $686 | $9 |
| Nitrofurantoin Mono-Macro | 15 | $312 | $21 |
| Sulfamethoxazole-Trimethoprim | 50 | $278 | $6 |
| Ciprofloxacin | 59 | $228 | $4 |
| Hydrocodone-Acetaminophen | 18 | $107 | $6 |
| Acetaminophen-Codeine | 13 | $48 | $4 |
2018: 16 drugs
| Myrbetriq | 74 | $37,052 | $501 |
| Tamsulosin | 517 | $12,951 | $25 |
| Vesicare | 32 | $12,900 | $403 |
| Oxybutynin Chloride Er | 137 | $9,205 | $67 |
| Toviaz | 12 | $5,951 | $496 |
| Rapaflo | 12 | $4,862 | $405 |
| Finasteride | 259 | $4,593 | $18 |
| Nitrofurantoin | 42 | $1,900 | $45 |
| Dutasteride | 37 | $1,653 | $45 |
| Bicalutamide | 23 | $803 | $35 |
| Alfuzosin Hcl Er | 29 | $676 | $23 |
| Cephalexin | 65 | $590 | $9 |
| Ciprofloxacin | 63 | $338 | $5 |
| Sulfamethoxazole-Trimethoprim | 39 | $144 | $4 |
| Hydrocodone-Acetaminophen | 23 | $139 | $6 |
| Acetaminophen-Codeine | 11 | $42 | $4 |
2017: 18 drugs
| Myrbetriq | 41 | $17,136 | $418 |
| Vesicare | 42 | $16,268 | $387 |
| Tamsulosin | 436 | $13,913 | $32 |
| Oxybutynin Chloride Er | 142 | $7,799 | $55 |
| Cialis | 23 | $7,017 | $305 |
| Finasteride | 269 | $4,237 | $16 |
| Nitrofurantoin | 57 | $2,376 | $42 |
| Dutasteride | 36 | $1,625 | $45 |
| Bicalutamide | 28 | $1,034 | $37 |
| Doxazosin Mesylate | 16 | $670 | $42 |
| Nitrofurantoin Mono-Macro | 13 | $664 | $51 |
| Alfuzosin Hcl Er | 25 | $497 | $20 |
| Cephalexin | 51 | $465 | $9 |
| Levofloxacin | 23 | $345 | $15 |
| Ciprofloxacin | 40 | $241 | $6 |
| Acetaminophen-Codeine | 31 | $115 | $4 |
| Hydrocodone-Acetaminophen | 17 | $82 | $5 |
| Sulfamethoxazole-Trimethoprim | 27 | $80 | $3 |
2016: 15 drugs
| Vesicare | 40 | $14,639 | $366 |
| Myrbetriq | 44 | $14,183 | $322 |
| Tamsulosin | 368 | $12,826 | $35 |
| Finasteride | 259 | $5,497 | $21 |
| Oxybutynin Chloride Er | 106 | $5,259 | $50 |
| Rapaflo | 20 | $4,209 | $210 |
| Dutasteride | 40 | $4,056 | $101 |
| Nitrofurantoin | 46 | $1,519 | $33 |
| Potassium Citrate Er | 13 | $1,318 | $101 |
| Nitrofurantoin Mono-Macro | 16 | $663 | $41 |
| Bicalutamide | 13 | $490 | $38 |
| Cephalexin | 47 | $441 | $9 |
| Alfuzosin Hcl Er | 12 | $390 | $32 |
| Ciprofloxacin | 40 | $317 | $8 |
| Acetaminophen-Codeine | 28 | $150 | $5 |
2015: 16 drugs
| Tamsulosin | 397 | $16,082 | $41 |
| Vesicare | 44 | $15,642 | $355 |
| Avodart | 44 | $12,929 | $294 |
| Myrbetriq | 32 | $8,734 | $273 |
| Finasteride | 303 | $5,099 | $17 |
| Oxybutynin Chloride Er | 79 | $4,680 | $59 |
| Enablex | 11 | $3,911 | $356 |
| Potassium Citrate Er | 22 | $1,853 | $84 |
| Nitrofurantoin | 40 | $1,283 | $32 |
| Bicalutamide | 19 | $673 | $35 |
| Cephalexin | 57 | $389 | $7 |
| Levofloxacin | 11 | $271 | $25 |
| Alfuzosin Hcl Er | 16 | $256 | $16 |
| Ciprofloxacin | 38 | $237 | $6 |
| Acetaminophen-Codeine | 27 | $121 | $4 |
| Sulfamethoxazole-Trimethoprim | 15 | $88 | $6 |
2014: 14 drugs
| Vesicare | 76 | $22,045 | $290 |
| Avodart | 39 | $11,314 | $290 |
| Tamsulosin | 373 | $8,969 | $24 |
| Finasteride | 249 | $5,300 | $21 |
| Myrbetriq | 17 | $4,176 | $246 |
| Toviaz | 11 | $3,359 | $305 |
| Oxybutynin Chloride Er | 38 | $2,674 | $70 |
| Nitrofurantoin | 38 | $1,747 | $46 |
| Bicalutamide | 12 | $410 | $34 |
| Cephalexin | 41 | $275 | $7 |
| Ciprofloxacin | 33 | $167 | $5 |
| Hydrocodone-Acetaminophen | 19 | $141 | $7 |
| Terazosin | 12 | $100 | $8 |
| Sulfamethoxazole-Trimethoprim | 14 | $89 | $6 |
2013: 14 drugs
| Avodart | 63 | $14,036 | $223 |
| Vesicare | 45 | $10,970 | $244 |
| Tamsulosin | 303 | $7,062 | $23 |
| Finasteride | 235 | $7,061 | $30 |
| Enablex | 15 | $3,233 | $216 |
| Detrol La | 11 | $2,575 | $234 |
| Nitrofurantoin | 49 | $2,242 | $46 |
| Oxybutynin Chloride Er | 30 | $1,868 | $62 |
| Cephalexin | 35 | $277 | $8 |
| Ciprofloxacin | 46 | $266 | $6 |
| Doxazosin Mesylate | 19 | $211 | $11 |
| Terazosin | 17 | $144 | $8 |
| Hydrocodone-Acetaminophen | 34 | $128 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $77 | $7 |
Money from drug and device companies
$432 in 2025
| 2025 | 4 | 4 | None | $432 |
| 2024 | 4 | 9 | None | $1,423 |
| 2022 | 2 | 3 | None | $750 |
| 2021 | 4 | 5 | None | $4,427 |
| 2020 | 2 | 7 | None | $334 |
| 2019 | 4 | 7 | None | $788 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Spaceoar Vue System - 10ml | $159 | 1 payment
|
| Janssen Biotech | Rybrevant | $122 | 1 payment
|
| Ferring Pharmaceuticals | Adstiladrin | $116 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $35 | 1 payment
|
See all 4 published payments
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-19 | Imfinzi | $35 |
| Janssen Biotech | Meals · 2025-10-29 | Rybrevant | $122 |
| Ferring Pharmaceuticals | Meals · 2025-04-23 | Adstiladrin | $116 |
| Boston Scientific | Meals · 2025-02-26 | Spaceoar Vue System - 10ml | $159 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $1,423
| Edap Technomed | None | $1,242 | 6 payments
|
| Janssen Biotech | Erleada | $146 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam System | $21 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $14 | 1 payment
|
2022: $750
| Dentsply Sirona | None | $650 | 2 payments
|
| Dornier MedTech America | Dornier Medtech | $100 | 1 payment
|
2021: $4,427
| Intuitive Surgical | Da Vinci Surgical System | $4,150 | 2 payments
|
| Dornier MedTech America | Consumables & Accessories | $224 | 1 payment
|
| Boston Scientific | Spaceoar Vue | $34 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $20 | 1 payment
|
2020: $334
| Astellas Pharma US | Xtandi | $191 | 3 payments
|
| Pfizer | Xtandi | $143 | 4 payments
|
2019: $788
| Intuitive Surgical | Da Vinci Surgical System | $600 | 2 payments
|
| Janssen Biotech | Erleada | $121 | 1 payment
|
| Pfizer | Xtandi | $47 | 3 payments
|
| Astellas Pharma US | Xtandi | $21 | 1 payment
|
Professional record
- NPI
- 1619048972
- Licence
- CA A83102California A83102: Current · expires 2028-09-30
- Trained
- Js Weill Medical College, Cornell University, 1995
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-11-10
- NPI last updated
- 2020-05-13
- NPI record certified
- 2020-05-13
This is when the NPI record was last certified, not a medical board exam.